Develop a Nasal Influenza Vaccine: Trinity College Dublin Leads Immunology Research in Ireland

Seasonal influenza remains one of the most persistent global health challenges, causing an estimated 1 billion infections annually. Despite the widespread availability of vaccines, the primary approach to immunization has remained largely unchanged for decades. Now, a team of researchers at Trinity College Dublin is challenging the status quo by pioneering advanced nasal vaccine development. By shifting the site of vaccine delivery from the muscle to the respiratory tract, this immunology research in Ireland aims to close a critical gap in how we prevent viral transmission.

Understanding the Limitations of Traditional Injected Influenza Vaccines

For years, the standard influenza vaccine has been administered via intramuscular injection. While this method is highly effective at preventing severe illness and reducing hospitalization rates, it exhibits a notable blind spot: it does not adequately stop the virus from entering the body or spreading to others.

Injectable vaccines are designed to stimulate a systemic immune response, primarily generating Immunoglobulin G (IgG) antibodies that circulate in the bloodstream. When a vaccinated person inhales the influenza virus, the pathogen bypasses these circulating antibodies and attaches directly to the mucosal surfaces of the upper respiratory tract. The virus begins replicating locally before the systemic immune system fully mobilizes. As a result, a vaccinated individual might still experience mild respiratory symptoms and, crucially, can still transmit the virus to unprotected individuals.

To truly mitigate the economic and health burdens of seasonal influenza, the scientific community recognizes the need to intercept the virus exactly where it establishes its initial foothold. Explore our related articles for further reading on immunology breakthroughs.

The Critical Role of Mucosal Immunity in Nasal Vaccine Development

The human respiratory tract is lined with a complex mucosal immune system that serves as the body’s first line of defense against inhaled pathogens. Unlike systemic immunity, mucosal immunity relies heavily on a specialized antibody class known as Immunoglobulin A (IgA), which is secreted directly across the mucosal surfaces.

When effectively stimulated, mucosal IgA can bind to the influenza virus immediately upon entry, neutralizing it before it can attach to host cells and replicate. Furthermore, nasal vaccine development seeks to activate tissue-resident memory T cells in the respiratory tract. These localized T cells can rapidly recognize and destroy infected cells, halting viral replication in its tracks.

Historically, generating a robust and durable mucosal immune response through a nasal spray has proven difficult. The nasal cavity presents unique physiological barriers, including mucociliary clearance mechanisms that rapidly sweep away foreign substances before they can interact with the immune system. Overcoming this biological hurdle requires sophisticated formulation strategies.

Inside the Lavelle Flu Lab: Engineering the C100 Adjuvant

At the Trinity Biomedical Sciences Institute, Professor Ed Lavelle and researcher Dorian Dederko are leading a project to solve this exact challenge. Their work centers on a first-in-class, patent-filed adjuvant named C100. An adjuvant is an ingredient added to a vaccine to enhance the body’s immune response to the provided antigen.

The C100 adjuvant operates through a dual-action mechanism that makes it uniquely suited for mucosal delivery. First, it possesses strong bio-adhesive properties, allowing it to cling to the mucosal surfaces of the nasal cavity and resist being cleared by the body’s natural mucociliary processes. Second, it provides potent innate immune activation. By engaging localized immune sensors, C100 signals the body to mount a powerful, targeted defense exactly where the vaccine is deposited.

This combination of bio-adhesion and immune stimulation enables the C100-adjuvanted formulation to drive the robust T cell responses and local IgA antibody production that are largely absent from current intramuscular vaccines. Schedule a free consultation to learn more about academic pathways in immunology.

Repurposing Existing Formulations to Accelerate Clinical Timelines

Rather than developing a completely new antigen from scratch, the Trinity College Dublin team is taking a strategic approach by repurposing an existing, licensed injectable influenza vaccine. By pairing a known and proven antigen with their novel C100 adjuvant, they can bypass years of early-stage antigen discovery and safety profiling.

This strategy of repurposing is highly advantageous for public health. It significantly shortens the timeline required to bring a transmission-blocking vaccine to market. The project has secured approximately €650,000 in funding from Flu Lab, a US-based organization dedicated to advancing innovative approaches for the prevention and treatment of influenza. This financial backing underscores the global scientific community’s confidence in the potential of mucosal vaccine platforms.

Implications for Global Pandemic Preparedness and Public Health

The development of a broadly protective, transmission-blocking influenza vaccine carries profound implications for global public health. Seasonal influenza epidemics place immense strain on healthcare systems, result in millions of severe cases, and cause hundreds of thousands of respiratory deaths globally each year. A vaccine that stops transmission could drastically reduce these numbers by establishing herd immunity more effectively.

Beyond seasonal strains, this immunology research in Ireland directly contributes to pandemic preparedness. The influenza virus is highly prone to antigenic drift and shift, processes that can generate novel pandemic strains against which the human population has little to no immunity. A nasal vaccine platform that can be rapidly adapted to target new antigens—while simultaneously providing robust local mucosal protection—would be an invaluable tool in the early stages of a novel outbreak. Stopping a novel virus at the point of entry in the upper respiratory tract is far more effective than trying to treat systemic viral pneumonia after the fact. Share your experiences in the comments below regarding the future of vaccine technology.

Advancing Toward Phase 1 Human Clinical Trials

The current phase of the Lavelle Flu Lab project focuses heavily on preclinical evaluation. Researchers must rigorously establish the efficacy, safety, and durability of the mucosal immune cell responses generated by the C100-adjuvanted nasal influenza vaccine. Durability is a particularly critical metric, as a practical vaccine must provide protection that lasts throughout an entire flu season without requiring frequent booster doses.

Upon the successful completion of these preclinical studies, the program will be positioned to advance to Phase 1 human clinical translation. Phase 1 trials primarily evaluate the safety and tolerability of the vaccine in a small cohort of healthy human volunteers, while also continuing to assess the human immune response. Moving a novel nasal adjuvant into human trials represents a significant milestone in vaccine research, bridging the gap between laboratory bench work and patient care.

Ireland’s Expanding Role in Global Biomedical Innovation

This initiative highlights the robust capacity of Ireland’s biomedical sector. The Trinity Biomedical Sciences Institute (TBSI) provides a state-of-the-art environment that fosters interdisciplinary collaboration between biochemists, immunologists, and clinical researchers. Facilities like TBSI are crucial for conducting the highly specialized assays required to measure mucosal T cell phenotypes and secretory IgA levels.

Trinity College Dublin has consistently maintained a strong reputation in fundamental immunology research. By applying these foundational scientific principles to a pressing, real-world clinical problem, Irish researchers are demonstrating their ability to compete on the global stage. The collaboration with an international funder like Flu Lab further cements Ireland’s position as an active participant in the global network of infectious disease research. Submit your application today to join leading research institutions driving biomedical innovation.

Redefining Respiratory Protection

The shift from intramuscular injections to intranasal delivery represents a fundamental paradigm shift in how we approach respiratory viral threats. By focusing on the mechanics of mucosal bio-adhesion and local immune activation, the team at Trinity College Dublin is addressing the specific weaknesses of current vaccine technologies.

While an injectable influenza vaccine will continue to play a vital role in preventing severe disease, the integration of a transmission-blocking nasal vaccine could provide the missing piece in the public health puzzle. As the Lavelle Flu Lab progresses through preclinical testing and toward human trials, the global health community watches closely. The successful translation of the C100-adjuvanted vaccine could mark the beginning of a new era in influenza control, one where stopping the spread of the virus is just as important as treating its symptoms. Have questions? Write to us!